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Abstract: The cognitive deficits in patients with HIV profoundly affect the quality of life 
of people living with this disease and have often been linked to the neuro-inflammatory 
condition known as HIV encephalitis (HIVE). With the advent of more effective anti-
retroviral therapies, HIVE has shifted from a sub-acute to a chronic condition. The 
neurodegenerative process in patients with HIVE is characterized by synaptic and dendritic 
damage to pyramidal neurons, loss of calbindin-immunoreactive interneurons and myelin 
loss. The mechanisms leading to neurodegeneration in HIVE might involve a variety of 
pathways, and several lines of investigation have found that interference with signaling 
factors mediating neuroprotection might play an important role. These signaling pathways 
include, among others, the GSK3, CDK5, ERK, Pyk2, p38 and JNK cascades. Of these, 
GSK3 has been a primary focus of many previous studies showing that in infected 
patients, HIV proteins and neurotoxins secreted by immune-activated cells in the brain 
abnormally activate this pathway, which is otherwise regulated by growth factors such as 
FGF. Interestingly, modulation of the GSK3 signaling pathway by FGF1 or GSK3 
inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot 
clinical trials have demonstrated cognitive improvements in HIV patients treated with 
GSK3 inhibitors. In addition to the GSK3 pathway, the CDK5 pathway has recently 
been implicated as a mediator of neurotoxicity in HIV, and HIV proteins might activate 
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this pathway and subsequently disrupt the diverse processes that CDK5 regulates, 
including synapse formation and plasticity and neurogenesis. Taken together, the GSK3 
and CDK5 signaling pathways are important regulators of neurotoxicity in HIV, and 
modulation of these factors might have therapeutic potential in the treatment of patients 
suffering from HIVE. In this context, the subsequent sections will focus on reviewing the 
involvement of the GSK3 and CDK5 pathways in neurodegeneration  in HIV. 
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1. Introduction 
The control and eradication of the neurological complications associated with AIDS continues to be 
an important goal in efforts toward improving the well-being of patients with HIV. In the central 
nervous system (CNS) of these patients, brain microglial cells are a primary reservoir for HIV-1 
infection [1,2]. These immune-activated cells secrete neurotoxins and produce HIV-1 proteins that 
contribute to the development of HIV-associated cognitive impairment (HACI) [3]. This progressive 
neurologic disease is characterized clinically by cognitive deficits that profoundly affect the quality of 
life of people living with this condition. Cognitive impairment in patients with HIV infection has often 
been linked to HIV encephalitis (HIVE) [4], a neuro-inflammatory condition [2,5] characterized by the 
presence of HIV-infected microglial cells, formation of microglial nodules, multinucleated giant cells, 
astrogliosis, myelin loss and neurodegeneration [6,7].  
With the advent of highly active antiretroviral therapies (HAART), the abundance of HIV in the 
brain and overt dementia has declined, however as the number of treated subjects with chronic HIV 
infection increases, the prevalence of HACI is actually rising, despite HAART [8-11]. It is now 
becoming apparent that these patients may be suffering from protracted forms of HIVE [7,8] that 
might lead to more subtle cognitive alterations rather than to overt dementia [1,4,12,13]. Patients with 
protracted mild forms of HIVE sometimes display more severe neurodegenerative pathology 
characterized by the simplification of the synapto-dendritic structure of pyramidal neuronal 
populations in the neocortex, indicating that HIVE has transitioned from a subacute to a chronic 
condition [6]. Thus, identification of new targets that might protect the CNS from the toxic effects of 
HIV might be an important adjuvant therapy for patients with HACI.  
2. Molecular and cellular mechanisms of neurodegeneration in HIV Encephalitis 
The mechanisms leading to cognitive impairment and dementia in AIDS patients are complex and 
require further investigation. Various line of evidence indicate that when HIV-infected 
monocytes/macrophages activate neuro-inflammatory cells such as microglia and astrocytes [14-21], 
these cells produce chemokines, cytokines and neurotoxins that, in conjunction with secreted HIV 
proteins, damage the synapto-dendritic arbor of neurons [22], leading to neuronal dysfunction and cell 
death probably via apoptosis [23-32]. This model predicts that levels of HIV in the CNS might reflect 
the extent of the structural and functional pathology in the brain [33-35]. Most patients with florid 
HIVE display cognitive impairment that in some severe cases results in dementia [4]. However, about Int. J. Mol. Sci. 2009, 10                 
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a quarter of patients with evidence of HIVE at autopsy clinically are neurologically un-impaired. Most 
cases with no significant neuropathology are cognitively un-impaired, nonetheless approximately one 
third of cases with no evidence of HIVE display cognitive alterations [4]. 
The neurodegenerative process in patients with HIVE is characterized by synaptic and dendritic 
damage [36] to pyramidal neurons [36], loss of calbindin-immunoreactive interneurons [37] and 
myelin loss [38]. While disruption of the cortico-cortico connections might result in learning and 
attention deficits, hippocampal pathology is linked to memory loss, and cortico-striatal damage results 
in motor alterations [39]. In addition to the damage to mature neuronal circuitries, recent studies have 
shown that HIV proteins might contribute to the neurodegenerative process by interfering with 
neurogenesis in the hippocampus [40-43]. Neurogenesis in the dentate gyrus is an active process in the 
mature CNS and plays a key role in synaptic plasticity, memory, and learning [44,45]. Environmental 
enrichment has been shown to stimulate neurogenesis and improve performance in memory tasks in 
mice [46-48]. The wnt [49] GSK3 and the cyclin-dependent kinase (CDK) signaling pathways [50] 
play an important role in this process. Therefore, the neurodegenerative process leading to cognitive 
alterations in HIV patients includes both: 1) damage to the mature synapto-dendritic apparatus of 
developed neurons and 2) impaired ability of NPCs in the hippocampal dentate gyrus to generate new 
neurons (Figure 1).  
Figure 1. Mechanisms of HIV protein-induced neuronal damage. HIV protein-mediated 
activation of cell surface receptors (CXCR4, NMDA-R, Notch1) leads to alterations in 
signaling pathways such as GSK3 and CDK5. Under physiological conditions, these 
pathways modulate critical substrates involved in synaptic plasticity and neurogenesis, and 
dysregulation of these signaling cascades could result in synapto-dendritic damage and 
impaired neurogenesis. 
 
 
The mechanisms leading to neurodegeneration in HIVE might involve a variety of pathways 
including excitotoxicity [51,52], oxidative stress [23], mitochondrial dysfunction [53,54] and calcium 
dysregulation [55,56] (Figure 1). In addition, several lines of investigation have found that interference 
with signaling pathways mediating neuroprotection might also play an important role. Among them, 
previous studies have shown that HIV proteins abnormally activate the CDK5 [57,58], GSK3 [59,60] Int. J. Mol. Sci. 2009, 10                 
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and ERK [61,62] signaling pathways, which otherwise are regulated by fibroblast growth factors 
(FGFs) [63,64]. In addition to direct activation of these signaling pathways, HIV proteins have been 
shown to trigger the release of neurotoxic products such as platelet-activating factor (PAF), which also 
contribute to dysregulation of signaling pathways such as GSK3 [65]. Furthermore, HIV proteins 
trigger neurodegeneration by activating signaling pathways involved in apoptosis such as RNA-
activated protein kinase [66], Pyk2 [67], p38 and JNK [24,61,68]. Of these molecular pathways 
leading to neurodegeneration in patients with HIVE, the subsequent sections will focus on reviewing 
the involvement of the GSK3 and CDK5 pathways. 
2.1. Role of FGF1-mediated regulation of the GSK3 signaling pathway in the mechanisms of 
neurodegeneration and neuroprotection in HIVE 
Previous studies found that in patients with cognitive impairment and HIVE, neurodegeneration 
might be associated with a reduction in the expression of neurotrophic factors such as FGF1 [69]. In 
contrast, in a subset of patients with HIV with preserved cognitive performance, FGF1 levels are up-
regulated. Interestingly, neuronal populations prone to degenerate in patients with HIV are dependent 
on FGF1 and FGF2 and express FGF receptors and CXCR4 [6,63,70]. The FGFs belong to a family 13 
trophic factors that are involved in neurogenesis [71] and angiogenesis [72]. Since FGF1 and 2 are 
expressed in the CNS in neurons vulnerable to the neurotoxic effects of HIV proteins [69], this 
indicates that the molecular pathways modulating FGF1 effects might be important mediators of the 
signaling involved in neurodegeneration and neuroprotection in patients with HIV [73].  
In vitro studies in primary neurons and neuronal cell lines have shown that the neuroprotective 
effects of FGF1 and FGF2 are mediated by activation of PI3K-Akt that in turn inactivate GSK3 via 
phosphorylation at the Ser 9 residue [63,64]. In addition to FGF1 and FGF2, other growth factors that 
exert their effects via receptor tyrosine kinases also lead to inactivation of GSK3 through 
phosphorylation. These include growth factors such as insulin growth factor-1 (IGF-I), epidermal 
growth factor (EGF) and platelet-derived growth factor (PDGF) [74,75]. To further investigate the 
neuroprotective effects of GSK3 regulation by FGF1 in vivo, we generated lines of tg mice 
expressing the human FGF1 under a neuronal promoter (PDGF).  
Human FGF1 cDNA was obtained by reverse transcriptase polymerase chain reaction (RT-PCR) 
from human brains and cloned into PCRII vector (TA Cloning from Invitrogen, CA) and 100% fidelity 
of nucleotide sequence was confirmed by dideoxy sequencing. Subsequently the FGF1 cDNA 
fragment was subcloned into the PDGF transgene cassette. The PDGF promoter was a gift of Dr. 
Tucker Collins at Harvard Medical School. The final construct contains the PDGF promoter, SV40 
intron, hFGF1 cDNAs, and SV40 polyA (Figure 2A). Constructs were microinjected and 5 lines of 
founder mice were obtained. Of them, based on the levels of mRNA expression two transgenic lines 
(line 15 low expresser; line 12 moderate expresser) were selected. RPA and Western blot analysis 
showed that both lines expressed human (h)FGF1 at levels comparable to the levels in the human brain 
(Figure 2B-F). Immunocytochemical analysis confirmed that hFGF1 was primarily expressed by 
neurons in the neocortex, hippocampus and basal ganglia, regions selectively susceptible to the 
neurotoxic effects of HIV products. Both lines of hFGF1 tg mice were viable, bred well and the 
nervous system developed normally. To determine the effects of FGF1 expression on the GSK3 Int. J. Mol. Sci. 2009, 10                 
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signaling pathway, immunoblot analysis was performed with an antibody against phosphorylated 
GSK3. This showed that in the mouse line expressing moderate levels of hFGF1 (line 12), levels of 
phosphorylated GSK3 (inactive form) were increased, while levels of pGSK3 in the low expresser 
line (15) were similar to nontg controls (Figure 2C). 
Figure 2. Characterization of hFGF1 tg mice. (a) Construct expressing hFGF1 under the 
control of the PDGF promoter. (b) RPA analysis of FGF1 mRNA expression. (c) 
Immunoblot analysis of total FGF1 protein expression and inactivation of GSK3 in FGF1 
tg mice. (d) Semi-quantitative analysis of hFGF1 mRNA levels. (e) Semi-quantitative 
analysis of mFGF1 mRNA levels. (e) Semi-quantitative analysis of total FGF1 protein 
expression by immunoblot. 
 
 
In order to test the hypothesis that hFGF1 protects against the neurotoxic effects of HIV products, 
tg mice (3 mo old, 5 per group) from lines 12 and 15 received intracerebral gp120 injections (1mM, 
total 2µl) in the neocortex and hippocampus. In nontg mice (3 mo old, 5 per group), gp120 promoted 
significant neuronal damage and astrogliosis compared to nontg saline-treated mice (Figure 3). In 
hFGF1 tg mice from line 12 (moderate expresser) neurons were protected against the toxic effects of 
gp120, while line 15 mice (low expresser) were susceptible, supporting the contention that hFGF1 was 
bioactive and protected neurons in a dose-dependent manner, probably via inactivation of GSK3. Int. J. Mol. Sci. 2009, 10                 
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Therefore, treatments directed at increasing the expression of FGF1 or targeting the signaling 
pathways affected, such as GSK3, might represent a possible neuroprotective strategy. 
Figure 3. Protective effects of FGF1 expression against the toxic effects of HIV-gp120 in 
mice injected with gp120 protein. (a) Nontg mouse injected with saline. (b) A prominent 
lesion developed in nontg mice injected with gp120 protein. (c) hFGF1 tg mouse injected 
with saline. (d) In hFGF1 tg mice injected with gp120, the neurons are protected and no 
lesion is observed. (e) Semi-quantitative analysis of levels of MAP2 immunoreactivity in 
the hippocampus. (f) Semi-quantitative analysis of levels of MAP2 immunoreactivity in  
the cortex. 
 
2.2. Neuroprotective effects of GSK3 inhibition in HIV neurotoxicity 
Similar to FGF1-mediated neuroprotection against HIV toxicity, recent studies have shown that at 
low concentrations lithium—a GSK3 inhibitor—protects the CNS from toxins [76,77] via GSK3 
inactivation. Our previous studies have shown lithium pre-treatment is neuroprotective in mice that 
received intrahippocampal injections of recombinant gp120 protein [76]. To expand on these studies, 
and to investigate the protective effects of lithium-mediated regulation of GSK3 against HIV-gp120-
mediated toxicity in a tg model, mice expressing high levels of gp120 in the brain were treated with 
lithium and analyzed by immunocytochemistry and immunoblot. For this purpose, 4-month old gp120 
tg mice (n=6) received intraperitoneal injections of lithium chloride (2 mg/kg/day) (Sigma, St. Louis, 
MO) for 14 days, and 6 control mice received saline injections (100l/day for 14 days).  
Consistent with our previous study in lithium-treated mice that received intrahippocampal 
injections of gp120 [76], lithium treatment in gp120 tg mice protected the hippocampus of mice from 
gp120-mediated toxicity (Figure 4) [76]. Lithium ameliorated the dendritic damage in gp120 tg mice 
(Figure 4A-D). Similarly, pre-exposure of neuronal cultures to lithium significantly reduced gp120-
associated neurotoxicity [76] (Figure 4E). The protective effects of lithium in vitro were partially 
blocked by LY294002, an inhibitor of the PI3K/Akt/GSK3 pathway (Figure 4E). Immunoblot Int. J. Mol. Sci. 2009, 10                 
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analysis showed that lithium activates Akt and blocks GSK3 activity via phosphorylation at Ser 9 
(Figure 4F). This is consistent with previous studies showing that lithium and other inhibitors of 
GSK3 activation, such as valproic acid, protect the brain against HIV-associated neurotoxicity [78-
82]. Therefore, the neuroprotective effects of FGF1 and lithium or valproic acid involve targeting 
analogous pathways, namely the Akt/GSK3 signaling cascade. 
Figure 4. Neuroprotective effects of lithium in gp120 models via GSK3 and CDK5 
phosphorylation. (a-d) Amelioration of the dendritic pathology (MAP2) in gp120 tg mice 
treated with lithium (daily injections for 2 weeks). (e) The neuroprotective effects of 
lithium against gp120 in SH-SY5Y cells are mediated by Akt. (f, g) Lithium downregulates 
CDK5 hyperactivation and inactivates GSK3 via phosphorylation. 
 
 
In view of this evidence and previous studies showing that GSK3 activation is involved in the 
mechanisms of HIV neurotoxicity [60], we concluded that targeting the GSK3 pathway with lithium 
might be of value in the management of the cognitive impairment [76,81-83]. Remarkably, in a pilot 
clinical trial we found that treatment with lithium for 12 weeks significantly ameliorated the cognitive 
deficits in HIV patients [83]. Similarly, another pilot clinical trial demonstrated that valproic acid is 
well tolerated in patients and can ameliorate HACI [78,80]. Taken together, these studies support a 
role for the GSK3 signaling pathway as a potential therapeutic target in the treatment of neuroAIDS. 
Currently, we are in the process of extending the lithium studies as well as investigating the 
potential therapeutic value of analogous molecules and signaling targets. In this regard, it is becoming 
clear that the neuroprotective effects of FGF1 and lithium might involve regulation of other signaling 
cascades [84]. Immunoblot analysis of brain homogenates from gp120 tg mice treated with saline or 
lithium showed that in addition to activating Akt and blocking GSK3, lithium treatment also resulted 
in reduced levels of CDK5 expression (Figure 4F), but no effects were observed on p38 and SAPK. 
These findings support the contention that both the PI3K/Akt/GSK3 and the CDK5 signaling Int. J. Mol. Sci. 2009, 10                 
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pathways might be involved in mediating neurotoxicity in HIVE, and that regulation of CDK5 in 
pathological states might be an important target for neuroprotection. 
2.3. Role of the CDK5 pathway in the mechanisms of synaptic damage in HIVE 
Recently, and as part of a gene array study, we found that several components of the CDK5 
signaling pathway are altered in patients with HIVE [85]. Moreover, other studies have shown that 
activation of CDK5 by calpains contributes to HIV-induced neurotoxicity [58]. In the mature CNS 
CDK5 is the predominant CDK, and is expressed at high levels in neurons [86]. While in peripheral 
dividing tissues other CDKs function as regulators of the cell cycle, CDK5 is unique among the CDKs 
in that its primary role is in regulating the phosphorylation of a multitude of downstream targets 
involved in cytoskeletal and synaptic function, among other activities [87]. Through its diverse targets, 
CDK5 plays an important role in critical processes in both the mature and developing brain, including 
neurogenesis [50,88], neuronal migration [89], and synapse formation and plasticity [87,90,91]   
(Figure 5). 
CDK5 is a Ser-Thr protein kinase with postmitotic activity that phosphorylates KSP motifs on 
cytoskeletal proteins (MAP1b, tau, NF, nestin, DCX), synaptic proteins (PSD95, synapsin, cadherin) 
and transcription factors (MEF2) [92-94]. While in dividing neurons CDKs are activated by cyclins, in 
the nervous system CDK5 is activated by forming a complex with p35 or p39 [93,95] (Figure 5). In 
contrast to other CDKs, which are inhibited by the cell cycle regulator proteins p21 and p27 (Kip-1) 
[96], CDK5 activity is regulated primarily by the metabolism of the activating proteins p35   
and p39 [97]. 
Figure 5. Physiological role of p35-CDK5 signaling in neurons. In the brain, CDK5 is the 
predominant CDK and can be activated by p35/p39 and phosphorylation of p35 by CK1. 
CDK5 activation, in turn, results in phosphorylation of key substrates involved in synaptic 
plasticity (PSD95) and neurogenesis (DCX), among other processes. 
 
 
Regulated activation of the CDK5 pathway via p35 [98] plays an important role in neuronal 
development [99] and synaptic plasticity [86,91] (Figure 5). The p35/p39-CDK5 complex has been 
shown to be constitutively active, however CDK5 phosphorylation by casein kinase 1 (CK1) [100,101] Int. J. Mol. Sci. 2009, 10                 
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and CDK7 [102] at Ser159 also contribute to CDK5 activation. CDK5 can be further activated by 
phosphorylation at Tyr15 by Src-related tyrosine kinase [100]. However, it is unclear to what extent 
phosphorylation plays a role in the regulation of CDK5 activity, and most studies suggest that the 
primary mechanism controlling CDK5 activation is expression and metabolism of p35 [97].  
Synthesis of p35 is stimulated by NGF and BDNF [103] as well as by ECM molecules like laminin 
[104] (Figure 5). Interestingly, HIV-1 Tat inhibits NGF-induced Egr-1 transcriptional activity and 
consequent p35 expression in neural cells [57]. The phosphorylation of p35, which is catalyzed by 
CDK5, produces an upward shift observed by gel electrophoresis and can be utilized as an indicator of 
CDK5 activity [100]. Although regulated activation of CDK5 by p35 and p39 under physiological 
conditions promotes neuronal development [99], axonal transport and synaptic activity [86,87,91], 
recent evidence suggests that abnormal activation of the CDK5 pathway might be also involved in cell 
death and neurodegeneration [105-108] (Figure 6). In this regard, recent studies indicate that calpain I 
mediated cleavage of p35 into the N-truncated fragmented p25 results in hyperactivation of CDK5 
which in turn results in abnormal phosphorylation of toxic substrates that have been associated with 
cell death [106] (Figure 6). 
Figure 6. Potential mechanisms of HIV-induced neurodegeneration mediated by 
hyperactivation of CDK5. Activation of cell surface receptors by HIV proteins or cellular 
neurotoxins causes calcium influx, which might activate calpain and result in p35 cleavage 
into p25, which in turn hyperactivates CDK5. This leads to aberrant phosphorylation of 
CDK5 substrates involved in synaptic plasticity (PSD95, synapsin) and neurogenesis 
(DCX). Alterations in these critical functions might contribute to the underlying 
neurodegenerative process of HACI. 
 
 
For example, in AD, it has been proposed that amyloid- (A) protein triggers calpain-mediated 
cleavage of p35 into p10 and p25, which in turn results in uncontrolled activity of CDK5 and tau 
hyperphosphorylation [106]. Similarly, in the nervous systems of patients with AIDS, it is possible that 
HIV products such as gp120 might trigger calcium influx via chemokine or glutamate receptors. This, 
in turn, may stimulate calpain-mediated proteolysis of p35 into p25 and subsequent hyperactivation of 
CDK5 with abnormal substrate phosphorylation (Figure 6). Alternatively, HIV proteins might regulate Int. J. Mol. Sci. 2009, 10                 
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CDK5 activity by sequestering p35, or interfering with factors that modulate levels of p35 expression 
or stability. Since CDK5 plays a role both in synaptic function and neuronal development, then 
abnormal activation of this molecule by HIV proteins might not only impair the functioning of mature 
neurons but also contribute to alterations in neurogenesis.  
2.4. CDK inhibitors as potential neuroprotective therapies for HACI 
Although HAART is an indispensable tool for the management of the neurological complications 
associated with HIV neuro-invasion, this approach does not completely eradicate HIV from the CNS, 
nor does it provide protection from the neurotoxicity of HIV proteins. Therefore discovery and testing 
of neuroprotective agents continues to be an important goal as an adjuvant therapy for the cognitive 
and neurological complications of HIV. Efforts in this direction include the testing of NMDA-R 
blockers such as memantine [109-111]. In addition, we have recently shown in a pilot clinical trial that 
modulation of signaling pathways involved in neurodegeneration with lithium might have a potential 
role as a neuroprotective treatment in HIV patients [83]. Lithium’s effects involve regulation of 
GSK3 and probably CDK5 among other potential targets [84]. Interestingly, and as indicated before, 
both of these signaling pathways are altered in patients with HIVE. Although lithium [76,83] and 
valproic acid [78,80,81] might hold some promise as therapeutic regulators of the GSK3 and CDK5 
signaling pathways, it is necessary to test and develop new and more specific compounds that   
target CDK5.  
In recent years considerable efforts have been devoted at developing CDK inhibitors for the 
treatment of neoplastic, viral and neurodegenerative disorders [112]. Among them, roscovitine has 
been identified as a CDK5 inhibitor with therapeutic potential. This compound belongs to the family of 
purine-derived CDK inhibitors that includes olomoucine and purvalanols [113]. Roscovitine crosses 
the blood brain barrier [114] and has been shown to be protective in experimental models of 
neurotoxicity [115]. This compound has been shown to be safe in humans and in clinical trials for glial 
cell tumors has been shown to have a promising effect. Roscovitine also blocks to a lesser extent 
cdc42, CDK2 and ERK [113]. Remarkably, CDK inhibitors are also under development as anti-
retroviral agents, because HIV recruits these kinases for viral replication in mitotic cells [112]. Of the 
CDK inhibitors, flavopiridol, which targets CDK1, 2, 4, 7 and 9, in combination with roscovitine, 
appears to be effective [112]. Thus CDK inhibitors could target both the viral infection as well as the 
pathogenic mechanism. 
3. Conclusions 
Given that HIV persists in the CNS, then elucidating the signaling pathways involved in mediating 
the neurotoxic effects of HIV are critical in the development of neuroprotective therapies that might 
act in conjunction with anti-retroviral therapies. In this context, both the GSK3 and CDK5 signaling 
cascades mediate some of the neurotoxic effects of HIV proteins (Figure 7). Modulation of these 
pathways by growth factor (FGF1)-based approaches, or with GSK3 inhibitors (lithium, valproic 
acid) or CDK5 inhibitors (Roscovitine) holds promise for the development of treatments that may 
ameliorate the neuropathological effects exerted by HIV proteins. Int. J. Mol. Sci. 2009, 10                 
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Figure 7. Schematic diagram showing the role of the GSK3 and CDK5 signaling 
pathways in mediating the toxic effects of HIV proteins. HIV proteins and cellular 
neurotoxins might stimulate the GSK3 and CDK5 signaling pathways via receptor 
interactions, resulting in the downstream disruption of processes involved in regulating 
synaptic and neuronal integrity. Growth factors such as FGF1, or other inhibitors of 
GSK3 signaling, might ameliorate these effects by antagonizing the activation of GSK3 
by HIV proteins and cellular neurotoxins. GSK3 and CDK5 share several downstream 
targets (e.g. Tau), and simultaneous activation of both of these pathways may exacerbate 
the neurotoxic effects of HIV proteins. 
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